Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Go back to Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)| Merck & Co. (NYSE: MRK) | Delayed: 150.91 +1.41 (0.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $149.50 | 52 Week High | $65.46 | |||
| Open | $148.69 | 52 Week Low | $47.97 | |||
| Day High | $153.57 | P/E | 102.66 | |||
| Day Low | $148.04 | EPS | $1.47 | |||
| Volume | 11,172,873 | |||||
